Good MorningEquities began the week on stable footing despite the previous week's large decline and the upcoming FOMC announcement on Wednesday. The Fed is expected to raise interest rates by 75 basis points on Wednesday and provide an outlook for the future of Fed policy. It is largely believed the Fed will continue to raise rates into the beginning of 2023 but at a much slower pace than what it has set so far. The risk is that inflation data will continue to accelerate as it has and push the Fed into ramping its posture once again.
On the economic front, the NAHB home builders survey declined to a new low as demand and traffic dry up. The news is only the latest in a string of poor housing data that points to a major contraction in the industry and one that will have rippling effects throughout the economy. Also on tap this week is a read on building permits and housing starts as well as existing home sales and the Index of Leading Indicators. Featured: 4 Bear-Proof Stocks (PTR) 
|
Markets | | | Database and cloud solutions provider Oracle (NASDAQ: ORCL) stock got smoked on its fiscal Q1 2023 earnings report. Shares were holding up relatively well until the Company revealed the extent of damage from FX related headwinds. Up until 2022, FX headwinds didn’t really impact stocks too much... Read the Full Story >> |
|
From Our PartnersIt could be true, according to Nevada Governor Steve Sisolak. The state's desert flats contain more lithium than any other geography in the world. And with electric vehicles driving a global boom in demand for lithium-ion batteries, Nevada should be on every investor's radar. | | Find Out How to Take Advantage of Nevada's Lithium Bonanza |
|
Markets | | |
McDonald’s continues to be able to deliver growth
McDonald’s goes about its business ringing up sales to value-minded eaters
McDonald’s has a steady history of quarterly dividend distributions
Just like you know what you’re getting when you order the number 5 value m... Read the Full Story >> |
|
Politics | | | Asian shares mostly rose Tuesday, after Wall Street closed higher on a late buying spree following recent losses as investors await another interest rate increase by the U.S. Federal Reserve.
Markets have been jittery over whether the Fed’s plan to cool the hottest U.S. inflation in f... Read the Full Story >> |
|
From Our PartnersAffordable, user-friendly robots are no longer sci-fi, thanks to Ally Robotics. They made a robot that costs 70% less to build. It learns by imitating human movement, no coding required. And it already has a $30M letter of intent to work in food service. | | Invest in Ally Robotics before their raise ends on |
|
Markets | | |
The market for Autozone (NYSE: AZO) stock pulled back from a fresh all-time high ahead of the FQ4 earnings release because there was cause for concern. Not only was the stock trading at an above-average P/E for the S&P 500 (NYSEARCA: SPY) and well above its peer Advance Auto Parts (NYSE: AAP) ... Read the Full Story >> |
|
Politics | | | Germany's natural gas storage facilities are now more than 90% full in preparation for the winter heating season and rising steadily despite Russia cutting off deliveries through a major pipeline, authorities said.
The head of the national network regulator, Klaus Mueller, tweeted lat... Read the Full Story >> |
|
From Our PartnersThe first step to trading penny stocks successfully is you've got to be in the stocks that have the highest probability of making a strong run. But how do you know which ones will be the big movers? These four low-priced stocks could deliver for investors in a big way. | | Click here to get the names of all 4 penny stocks. |
|
Politics | | | Hungary needs time and is urging its European Union partners to be “tolerant,” the country's justice minister said Tuesday, after the bloc's executive branch recommended suspending billions of euros in funding over concerns about democratic backsliding and the possible mismanagement of EU money.
... Read the Full Story >> |
|
Politics | | | Global shares mostly rose Tuesday, after Wall Street closed higher on a late flurry of buying as investors awaited another interest rate increase by the U.S. Federal Reserve.
France's CAC 40 slipped 0.5% in early trading to 6,034.21. Germany's DAX lost 0.3% to 12,763.74. Britain's FTS... Read the Full Story >> |
|
Politics | | | Germany remains committed to phasing out coal as a source of power by 2030 even as it reactivates coal-fired power plants, the country's climate envoy said Monday. Germany says it took the step to get through the coming winter amid energy shortages as a result of Russia’s war in Ukraine.
... Read the Full Story >> |
|
Stocks | | |
Lucid is in a better financial position than most upstart EV players
The near-term headwinds should matter little in the long haul
Lucid noted that its liquidity position will keep it running well into 2023
Like most electric vehicle plays, Lucid Group, Inc. (NASDAQ: LCID) has had its shar... Read the Full Story >> |
|
Markets | | |
FedEx (NYSE: FDX) fired a warning shot the market needs to pay attention to when it prereleasedQ3 earnings but there is more to the story than what the headlines are screaming. FedEx is predicting a global recession in 2023 but the 20% decline in share prices is already offering a buying opportuni... Read the Full Story >> |
|
The Early Bird Stock Of The DayTuesday: Stock Being Upgraded Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York. | | View Today's Stock Pick |
|
